Clinical Trial Update: Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating the efficacy and safety of DR10624 Injection in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• DR10624 Injection

Snippet

Sponsor: Zhejiang Doer Biologics Co., Ltd. | Conditions: MASLD | Phase 2 | Status: ACTIVE_NOT_RECRUITING